Is entecavir ideal for the treatment of lamivudine‐refractory chronic hepatitis B?
Chien‐Wei Su, Jaw‐Ching Wu, Shou‐Dong Lee – 28 October 2008
Chien‐Wei Su, Jaw‐Ching Wu, Shou‐Dong Lee – 28 October 2008
Michele A. Rodrigues, Dawidson A. Gomes, Viviane A. Andrade, M. Fatima Leite, Michael H. Nathanson – 28 October 2008 – Insulin is an hepatic mitogen that promotes liver regeneration. Actions of insulin are mediated by the insulin receptor, which is a receptor tyrosine kinase. It is currently thought that signaling via the insulin receptor occurs at the plasma membrane, where it binds to insulin.
Martin Wagner, Gernot Zollner, Michael Trauner – 28 October 2008
Peter W. Angus, Scott J. Patterson, Simone I. Strasser, Geoffrey W. McCaughan, Edward Gane – 28 October 2008 – Prior to effective prophylaxis, liver transplantation for hepatitis B virus (HBV)‐related disease was frequently complicated by recurrence, which could be severe and rapidly progressive. Combination hepatitis B immunoglobulin (HBIG) and lamivudine prophylaxis reduces this rate of recurrence to <5% at 5 years; however, HBIG administration is costly and inconvenient.
Francesca Faggioli, Maria Grazia Sacco, Lucia Susani, Cristina Montagna, Paolo Vezzoni – 28 October 2008 – A large portion of hepatocytes are polyploid cells, thought to arise through endoduplication followed by aborted cytokinesis. However, several recent reports describing liver cell fusion with exogenously derived bone marrow cells have been published. The exact significance of this finding is unclear, because the adopted protocols involve ablation regimens, damaged livers and artificial injections of adult cells.
Chihiro Morishima, Timothy R. Morgan, James E. Everhart, Elizabeth C. Wright, Minjun C. Apodaca, David R. Gretch, Mitchell L. Shiffman, Gregory T. Everson, Karen L. Lindsay, William M. Lee, Anna S. F. Lok, Jules L. Dienstag, Marc G. Ghany, Teresa M. Curto, HALT‐C Trial Group – 28 October 2008 – The Siemens VERSANT® transcription‐mediated amplification (TMA) assay is extremely sensitive for the detection of hepatitis C virus (HCV) RNA in serum.
Blythe D. Shepard, Rohan A. Joseph, George T. Kannarkat, Tara M. Rutledge, Dean J. Tuma, Pamela L. Tuma – 28 October 2008 – We have been using polarized, hepatic WIF‐B cells to examine ethanol‐induced liver injury. These cells polarize in culture and maintain numerous liver‐specific activities including the ability to metabolize alcohol. Previously, we found that microtubules were more highly acetylated and more stable in ethanol‐treated WIF‐B cells and that increased microtubule acetylation required ethanol metabolism and was likely mediated by acetaldehyde.
Chuan Yin, Yong Lin, Xin Zhang, Yue‐Xiang Chen, Xin Zeng, Hai‐Yan Yue, Jun‐Liang Hou, Xing Deng, Jun‐Ping Zhang, Ze‐Guang Han, Wei‐Fen Xie – 28 October 2008 – Previous studies have shown that hepatocyte nuclear factor‐4α (HNF4α) is a central regulator of differentiated hepatocyte phenotype and forced expression of HNF4α could promote reversion of tumors toward a less invasive phenotype. However, the effect of HNF4α on cancer stem cells (CSCs) and the treatment of hepatocellular carcinoma (HCC) with HNF4α have not been reported.
Marija Zeremski, Lydia M. Petrovic, Luis Chiriboga, Queenie B. Brown, Herman T. Yee, Milan Kinkhabwala, Ira M. Jacobson, Rositsa Dimova, Marianthi Markatou, Andrew H. Talal – 28 October 2008 – Chemokines, chemotactic cytokines, may promote hepatic inflammation in chronic hepatitis C virus (HCV) infection through the recruitment of lymphocytes to the liver parenchyma.
Keun‐Gyu Park, Ae‐Kyung Min, Eun Hee Koh, Hyoun Sik Kim, Mi‐Ok Kim, Hye‐Sun Park, Yong‐Deuk Kim, Tae‐Seung Yoon, Byoung Kuk Jang, Jae Seok Hwang, Jae Bum Kim, Hueng‐Sik Choi, Joong‐Yeol Park, In‐Kyu Lee, Ki‐Up Lee – 28 October 2008 – Fatty liver is common in obese subjects with insulin resistance. Hepatic expression of sterol regulatory element binding protein‐1c (SREBP‐1c), which plays a major role in hepatic steatosis, is regulated by multiple factors, including insulin, adenosine monophosphate–activated protein kinase (AMPK), liver X receptors (LXRs), and specificity protein 1.